Comparative Pharmacology
Head-to-head clinical analysis: CAM AP ES versus QUTENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAM AP ES versus QUTENZA.
CAM-AP-ES vs QUTENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAM-AP-ES is a combination antihypertensive containing camphor, apocynum, and eserine. The mechanism involves camphor as a mild vasodilator, apocynum as a cardiac glycoside with positive inotropic and negative chronotropic effects, and eserine as a cholinesterase inhibitor that enhances parasympathetic activity, leading to reduced heart rate and vasodilation.
QUTENZA (capsaicin) is a transient receptor potential vanilloid 1 (TRPV1) agonist. It selectively binds to TRPV1 receptors on cutaneous nociceptors, causing initial excitation followed by defunctionalization and reduced sensitivity to pain.
CAM-AP-ES: Oral, 1-2 tablets twice daily. Each tablet contains camphor 30 mg, apomorphine 5 mg, and eserine 2 mg.
Topical patch applied to painful area for 60 minutes every 3 months (up to 4 patches per application).
None Documented
None Documented
Terminal elimination half-life 10–12 hours in normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
6.5 hours (range 5-8 hours) for systemic capsaicin; transient due to rapid metabolism. Clinically, local effects persist beyond systemic clearance.
Renal: ~90% unchanged drug; biliary/fecal: ~10% as metabolites
Primarily renal; capsaicin and metabolites excreted in urine, with <1% unchanged. Fecal elimination accounts for <5%.
Category C
Category C
Topical Analgesic
Topical Analgesic